tirzepatide cvot results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx 💡 New insight in diabetes

Put the top straight in the sharps box

"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," Dr

The rapid clinical adoption of glucagon-like peptide-1 (GLP-1) receptor agonists and related anti-obesity pharmacotherapies represents one of the most consequential therapeutic shifts in metabolic medicine in decades

You may need a higher dosage The effects of tirzepatide are dose-dependent, meaning that people who take higher dosage strengths tend to lose more weight (for what its worth, they may experience more side effects, too)